Life Science Leader Chief Editor Blog Header image Life Science Leader Chief Editor Blog Header image

How PhRMA Is Adapting To The Industry’s New Reality
How PhRMA Is Adapting To The Industry’s New Reality PhRMA held its 2016 annual meeting March 9 and 10 in Washington, D.C. This was the first annual meeting held under the new leadership regime of Stephen Ubl. Having spent more than 10 years as the president and CEO of the Advanced Medical Technology Association (AdvaMed), Ubl took the PhRMA helm just three days after former Turing Pharmaceutical CEO Martin Shkreli made national headlines with his drug-price increase antics.  Continue Reading...
R&D Leadership Summit Provides Ear-Opening Experience
R&D Leadership Summit Provides Ear-Opening Experience Life Science Leader magazine and CNBC were the only two members of the media invited to attend the 6th Annual R&D Leadership (RDL) Summit (I will explain why this is significant in a moment). Produced by the Conference Forum with support from PRA Health Sciences, the event provides an extremely intimate opportunity for R&D executives to network and openly discuss some of the biopharmaceutical industry’s most controversial issues (e.  Continue Reading...
What Will Be The End Result Of Bullying Biopharma?
What Will Be The End Result Of Bullying Biopharma? If as adults we could invisibly walk on school playgrounds during recess, we might hear the stock response recited when encountering a bully — ‘Sticks and stones may break my bones, but words will never hurt me.”  Continue Reading...
BIO CEO 2016 Educational Sessions Provide Enlightenment
BIO CEO 2016 Educational Sessions Provide Enlightenment During this year’s BIO CEO Conference (partially covered here), much of my time was spent in the educational sessions, which I would rank as some of the best I have seen at any conference — ever. For example, the CRISPR/Cas9: Excitement and Concern for First Therapies had three gene editing company CEOs (i.e., Katrine Bosley of Editas Medicine, André Choulika of Cellectis, and Sapna Srivastava, Intellia Therapeutics) as well...  Continue Reading...
Is Attending BIO CEO A Waste Of Your Time?
Is Attending BIO CEO A Waste Of Your Time? Sometimes it is worthwhile to stop and consider the value of your time, not from a financial perspective, but rather how much you’ve used and how much you have left. If you did, you might be much more discriminating in where you would choose to spend it. Consider this: the average U.S. male’s life expectancy is 76. This means that in less than 14,600 hours my time fuel tank will be exactly one-third full, or depending on your...  Continue Reading...
What Does It Take To Be The World’s Top Performing CEO?
What Does It Take To Be The World’s Top Performing CEO? In November 2015, the Harvard Business Review (HBR) announced the top 100 CEOs in the world. Though the list included household names like Starbucks (12), Nike (21), and Amazon (87), what is even more interesting than the fact that Novo Nordisk’s Lars Rebien Sørensen was ranked number one, was the healthcare industry as a whole had 13 CEOs in the top 100 — tying it for first with financial service (see Table 1). But if you dig ...  Continue Reading...
What Is The Solution To “High-Price” Drug Sticker Shock?
What Is The Solution To “High-Price” Drug Sticker Shock? Last November, lawmakers and the Obama administration began ratcheting up efforts targeted at pharmaceutical company’s “high-priced drugs.” Some view this as a sign that legislators are trying to bridge the political divide to tackle a key driver of rising healthcare costs. But are high-priced drugs and biopharmaceutical companies the most important driver to target? After all, research has shown that hospitals and physicians...  Continue Reading...
What Surprised Me — And Didn’t — At J.P. Morgan 2016
What Surprised Me — And Didn’t — At J.P. Morgan 2016 Unfortunately, a minor mechanical issue involving one of my flights caused me to arrive a day late for the 34th Annual J.P. Morgan Healthcare Conference (JPM) in San Francisco (January 11-14). While missing Monday at one of biopharma’s biggest annual events (Twitter hashtag #JPM16) translates to a huge lost opportunity (i.e., not being able to attend 16 of 108 scheduled presentations/breakout sessions), when it comes to JPM, one day does...  Continue Reading...
What Is Going To Be The Next Big Thing For Biopharma In 2016?
What Is Going To Be The Next Big Thing For Biopharma In 2016? There are plenty of industry insights available, such as Life Science Leader’s comprehensive December 2015 Outlook issue for 2016 or our four-part trendsetter series. And while these provide a wealth of insight, I felt compelled to put together one last blog to prevent you from being blindsided by the “Next Big Thing” in biopharma in 2016.  Continue Reading...
What Guides Your Company?
What Guides Your Company? If you have ever seen an employee of Johnson and Johnson speak, you probably recall that at some point during their presentation they probably made reference to “Our Credo” — a J&J document that describes the values used to guide employee decision making. “Put simply, Our Credo challenges us to put the needs and well-being of the people we serve first.” Written in 1943 by Robert Wood Johnson, former chairman and ...  Continue Reading...